Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 692342

Drug Profile

GSK 692342

Alternative Names: 692342; GSK M72; GSK-692342; M72/AS01E; M72/AS01E-4; Mtb72F/AS02A; Recombinant-tuberculosis-vaccine-GSK; SB-692342; Tuberculosis-vaccine-Aeras/GSK; Tuberculosis-vaccine-GSK; Tuberculosis-vaccine-Mtb72f/AS02A; Tuberculosis-vaccine-recombinant-fusion-protein-Mtb72f/AS02A

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Bill & Melinda Gates Medical Research Institute; GlaxoSmithKline; GSK
  • Class Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 05 Mar 2024 Phase-III clinical trials in Tuberculosis (In adolescents, In adults, Prevention) in South Africa (IM) (NCT06062238)
  • 03 Sep 2021 No development reported - Phase-II for Tuberculosis in Kenya (IM)
  • 03 Sep 2021 No development reported - Phase-II for Tuberculosis in Zambia (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top